Note: Ingredients listed on restricted chemical lists
EC/CAS
215-185-5/1310-73-2
Name of the chemical
sodium hydroxide
Concentration
<1
EC/CAS
231-791-2/7732-18-5
Name of the chemical
Water, distilled, conductivity or of similar purity H2O
Concentration
*
EC/CAS
201-766-0/87-69-4
Name of the chemical
L-(+)-tartaric acid
Concentration
*
General Information
Revision date
2020-03-19
Product name
Oxaliplatin Injection (Solution for Intravenous Use)
Chemical name
Not determined
Emergency telephone
1-800-424-9300, +1-703-527-3887
Icons in SDS
Company Information
company name
Hospira, A Pfizer Company
e-mail address of the competent person responsible for the Safety Data Sheet
pfizer-MSDS@pfizer.com
GHS Information
Signal word
Danger
Hazard Codes
Hazard statements (CLP)
H340, H360D
Hazard statements
Code
Statements
H340
May cause genetic defects
Section 2
2.1 Classification of the substance or mixture
Germ cell mutagenicity Category 1B - (H340) Reproductive toxicity Category 1B - (H360D)
Signal word
Danger
Hazard statements
H340 - May cause genetic defects H360D - May damage the unborn child
Precautionary statements
P321 - Specific treatment (see .? on this label) P201 - Obtain special instructions before use P280 - Wear protective gloves/protective clothing/eye protection/face protection P308 + P313 - IF exposed or concerned: Get medical advice/attention P202 - Do not handle until all safety precautions have been read and understood
Other hazards
An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8). Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.
